Bone drugs may raise risk of esophageal cancer, FDA official says

01/1/2009 | Reuters

FDA official Diane Wysowski said researchers should look into the potential risk of esophageal cancer tied to Merck & Co.'s Fosamax and other bisphosphonate drugs, which are designed to treat osteoporosis. In a letter published in a journal, she said Fosamax has been linked to 23 reports of esophageal tumors in the U.S. since its launch in 1995. Wysowski also advised physicians against using bisphosphonates for patients with Barrett's esophagus, a condition known to raise cancer risk.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park